PubMed:10656608 JSONTXT

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":209,"end":238},"obj":"HP_0030358"},{"id":"T2","span":{"begin":213,"end":238},"obj":"HP_0030357"},{"id":"T3","span":{"begin":807,"end":813},"obj":"HP_0002664"}],"text":"Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release.\nThe mu3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu3 profile. Our findings identify a unique role for the mu3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression."}

{"project":"DisGeNET5_gene_disease","denotations":[{"id":"10656608-3#112#130#gene4988","span":{"begin":529,"end":547},"obj":"gene4988"},{"id":"10656608-3#158#172#diseaseC0684249","span":{"begin":575,"end":589},"obj":"diseaseC0684249"}],"relations":[{"id":"112#130#gene4988158#172#diseaseC0684249","pred":"associated_with","subj":"10656608-3#112#130#gene4988","obj":"10656608-3#158#172#diseaseC0684249"}],"text":"Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release.\nThe mu3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu3 profile. Our findings identify a unique role for the mu3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression."}

{"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":529,"end":547},"obj":"gene:4988"},{"id":"T1","span":{"begin":575,"end":589},"obj":"disease:C0684249"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Mu3 opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release.\nThe mu3 opiate receptor subtype is expressed in human surgical specimens of both normal lung and non-small-cell lung carcinoma. Nitric oxide (NO) release is mediated through the mu3 receptor, and in lung carcinoma, morphine-stimulated NO release is significantly higher and prolonged than in normal lung. Using reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis we show that specific mu opioid receptor transcripts are present in lung carcinoma and other cells with the mu3 profile. Our findings identify a unique role for the mu3 opiate receptor in opiate-mediated NO release and suggest that endogenous opiates, through their release of NO, may play a role in cancer progression."}